Current targeted therapies in the treatment of advanced colorectal cancer: a review

No abstract is available for this paper.

• Publication year

  2016

• Venue

  Therapeutic Advances in Medical Oncology

• Publication date

  2016-05-29

• Fields of study

  Medicine

• Identifiers
  DOI 10.1177/1758834016646734PMID 27482287PMCID PMC4952023
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Ramucirumab, another anti-angiogenic agent for metastatic colorectal cancer in second-line setting—its impact on clinical practice

  2015cited by this paper
• Therapeutic potential of TAS-102 in the treatment of gastrointestinal malignancies

  2015cited by this paper
• TAS-102, a novel antitumor agent: a review of the mechanism of action.

  2015cited by this paper
• Randomized trial of TAS-102 for refractory metastatic colorectal cancer.

  2015cited by this paper
• Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study.

  2015cited by this paper
• FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial.

  2014cited by this paper
• The impact of KRAS mutations on VEGF-A production and tumour vascular network

  2013cited by this paper
• Rare Though Not Mutually Exclusive: A Report of Three Cases of Concomitant KRAS and BRAF Mutation and a Review of the Literature

  2013cited by this paper
• The prognostic role of KRAS, BRAF, PIK3CA and PTEN in colorectal cancer

  2013cited by this paper
• Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial.

  2013cited by this paper
• Comprehensive molecular characterization of human colon and rectal cancer

  2013cited by this paper
• Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial.

  2013cited by this paper
• Alternate dosing of cetuximab for patients with metastatic colorectal cancer.

  2013cited by this paper
• BRAF mutations in melanoma and colorectal cancer: a single oncogenic mutation with different tumour phenotypes and clinical implications.

  2013cited by this paper
• Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer.

  2013cited by this paper
• PIK3CA mutation is associated with poor survival among patients with metastatic colorectal cancer following anti-EGFR monoclonal antibody therapy: a meta-analysis

  2013cited by this paper
• Does anti-EGFR therapy improve outcome in advanced colorectal cancer? A systematic review and meta-analysis.

  2012cited by this paper
• Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen.

  2012cited by this paper
• The Prognostic Value of BRAF Mutation in Colorectal Cancer and Melanoma: A Systematic Review and Meta-Analysis

  2012cited by this paper
• Addition of cetuximab to chemotherapy as first-line treatment for KRAS wild-type metastatic colorectal cancer: pooled analysis of the CRYSTAL and OPUS randomised clinical trials.

  2012cited by this paper
• Aflibercept in the Treatment of Metastatic Colorectal Cancer

  2012cited by this paper
• Comprehensive molecular characterization of human colon and rectal cancer

  2012cited by this paper
• An update on the current and emerging targeted agents in metastatic colorectal cancer.

  2012cited by this paper
• Treatment with transcatheter arterial chemoembolization induces an increase of the L-selectinlow CXCR3+ CD8+ T cell subset in patients with hepatocellular carcinoma

  2012cited by this paper
• Cancer statistics, 2012

  2012cited by this paper
• EGFR-targeted therapy.

  2011cited by this paper
• Regorafenib (BAY 73‐4506): A new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity

  2011cited by this paper
• Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status.

  2011cited by this paper
• Endothelial progenitor cell biology in disease and tissue regeneration

  2011cited by this paper
• Frequency of KRAS, BRAF, and NRAS mutations in colorectal cancer

  2011cited by this paper
• Clinical outcome of panitumumab for metastatic colorectal cancer with wild-type KRAS status: a meta-analysis of randomized clinical trials

  2011cited by this paper
• Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study.

  2011cited by this paper
• Systematic Review: Anti–Epidermal Growth Factor Receptor Treatment Effect Modification by KRAS Mutations in Advanced Colorectal Cancer

  2011cited by this paper
• Ras in cancer and developmental diseases.

  2011cited by this paper
• Vascular Endothelial Growth Factor (VEGF) and Its Receptor (VEGFR) Signaling in Angiogenesis: A Crucial Target for Anti- and Pro-Angiogenic Therapies.

  2011influential reference
• Development of Second-Generation VEGFR Tyrosine Kinase Inhibitors: Current Status

  2011cited by this paper
• Cetuximab: from bench to bedside.

  2010cited by this paper
• NRAS Mutations Are Rare in Colorectal Cancer

  2010cited by this paper
• Antiangiogenesis agents in colorectal cancer

  2010cited by this paper
• Safety of bevacizumab in patients with advanced cancer: a meta-analysis of randomized controlled trials.

  2010cited by this paper
• How do tumours adapt to nutrient stress?

  2010cited by this paper
• Molecular determinants of anti-EGFR sensitivity and resistance in metastatic colorectal cancer

  2010cited by this paper
• Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008

  2010cited by this paper
• Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study.

  2010cited by this paper
• Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival.

  2010cited by this paper
• Advanced colorectal cancer: ESMO Clinical Practice Guidelines for treatment.

  2010cited by this paper
• Anti-angiogenesis therapies: their potential in cancer management

  2010cited by this paper
• Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis.

  2010cited by this paper
• Implications for KRAS status and EGFR-targeted therapies in metastatic CRC

  2009cited by this paper
• A randomized phase IIIB trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer.

  2009cited by this paper
• Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer.

  2009cited by this paper
• Dual-antibody therapy in advanced colorectal cancer: gather ye rosebuds while ye may.

  2009cited by this paper
• Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer.

  2009influential reference
• Linking somatic genetic alterations in cancer to therapeutics.

  2009cited by this paper
• Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial.

  2009cited by this paper
• The clinical benefit of bevacizumab in metastatic colorectal cancer is independent of K-ras mutation status: analysis of a phase III study of bevacizumab with chemotherapy in previously untreated metastatic colorectal cancer.

  2009cited by this paper
• Treatment in advanced colorectal cancer: what, when and how?

  2009cited by this paper
• Phase 2 open‐label study of single‐agent sorafenib in treating advanced hepatocellular carcinoma in a hepatitis B–endemic Asian population

  2009cited by this paper
• PI3KCA/PTEN deregulation contributes to impaired responses to cetuximab in metastatic colorectal cancer patients.

  2009cited by this paper
• Pharmacogenetics and biomarkers in colorectal cancer

  2009cited by this paper
• KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer

  2009cited by this paper
• KRAS mutations and sensitivity to epidermal growth factor receptor inhibitors in colorectal cancer: practical application of patient selection.

  2009cited by this paper
• Biomarker-Driven Early Clinical Trials in Oncology: A Paradigm Shift in Drug Development

  2009cited by this paper
• Targeting cancer with small molecule kinase inhibitors

  2009cited by this paper
• American Society of Clinical Oncology provisional clinical opinion: testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy.

  2009cited by this paper
• Wild-Type KRAS Is Required for Panitumumab Efficacy in Patients With Metastatic Colorectal Cancer

  2009cited by this paper
• ERBBs in the gastrointestinal tract: recent progress and new perspectives.

  2009cited by this paper
• Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: updated results from the BICC-C study.

  2008cited by this paper
• KRAS status and efficacy in the first-line treatment of patients with metastatic colorectal cancer (mCRC) treated with FOLFIRI with or without cetuximab: The CRYSTAL experience

  2008cited by this paper
• Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study.

  2008cited by this paper
• Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer.

  2008cited by this paper
• The Use of Genomics in Clinical Trial Design

  2008cited by this paper
• KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab.

  2008cited by this paper
• Combined targeting of EGFR-dependent and VEGF-dependent pathways: rationale, preclinical studies and clinical applications

  2008cited by this paper
• EGFR targeting of solid tumors.

  2007cited by this paper
• Antibody‐dependent cellular cytotoxicity of cetuximab against tumor cells with wild‐type or mutant epidermal growth factor receptor

  2007cited by this paper
• Randomized phase III study of irinotecan and 5-FU/FA with or without cetuximab in the first-line treatment of patients with metastatic colorectal cancer (mCRC): The CRYSTAL trial

  2007cited by this paper
• FDA drug approval summary: panitumumab (Vectibix).

  2007cited by this paper
• Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer.

  2007cited by this paper
• Phase II trial of cetuximab in combination with fluorouracil, leucovorin, and oxaliplatin in the first-line treatment of metastatic colorectal cancer.

  2007cited by this paper
• Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab.

  2007cited by this paper
• Randomized phase II trial of cetuximab, bevacizumab, and irinotecan compared with cetuximab and bevacizumab alone in irinotecan-refractory colorectal cancer: the BOND-2 study.

  2007cited by this paper
• Hyperactive Ras in developmental disorders and cancer

  2007cited by this paper
• Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies.

  2007cited by this paper
• The Genomic Landscapes of Human Breast and Colorectal Cancers

  2007cited by this paper
• Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200.

  2007cited by this paper
• Epidermal Growth Factor Receptor Antibody Therapies − Anti Impairs the Response of Metastatic Colorectal Cancers to Oncogenic Activation of the RAS / RAF Signaling Pathway

  2007cited by this paper
• Minimally invasive pharmacokinetic and pharmacodynamic technologies in hypothesis-testing clinical trials of innovative therapies.

  2006cited by this paper
• Inhibition of VEGFR-3 activation with the antagonistic antibody more potently suppresses lymph node and distant metastases than inactivation of VEGFR-2.

  2006cited by this paper
• Bevacizumab plus Irinotecan,Fluorouracil,and Leucovorin for Metastatic Colorectal Cancer

  2006cited by this paper
• Rational design of inhibitors that bind to inactive kinase conformations

  2006influential reference
• Estimates of the cancer incidence and mortality in Europe in 2006.

  2006cited by this paper
• EGF–ERBB signalling: towards the systems level

  2006cited by this paper
• Cetuximab Monotherapy and Cetuximab plus Irinotecan in Irinotecan-Refractory Metastatic Colorectal Cancer

  2006cited by this paper
• Colon Cancer Survival Rates With the New American Joint Committee on Cancer Sixth Edition Staging

  2006cited by this paper
• Phase II trial of paclitaxel, carboplatin, and etoposide in advanced poorly differentiated neuroendocrine carcinoma: a Minnie Pearl Cancer Research Network Study.

  2006cited by this paper
• Mechanisms of action of bevacizumab as a component of therapy for metastatic colorectal cancer.

  2006influential reference
• Panitumumab

  2006cited by this paper
• Panitumumab antitumor activity in patients (pts) with metastatic colorectal cancer (mCRC) expressing ≥ 10% epidermal growth factor receptor (EGFr).

  2006cited by this paper
• ERBB receptors and cancer: the complexity of targeted inhibitors

  2005influential reference

• A biologically constrained agent-based model of cancer stem cell dynamics with reinforcement learning-guided adaptive radiotherapy

  2026cites this paper
• Discovery of 8-sulfonamidoquinolines as anti-proliferative agents against colorectal cancer: design, synthesis, and biological evaluation.

  2026cites this paper
• Focus on PD-1/PD-L1-Targeting Antibodies in Colorectal Cancer: Are There Options Beyond Dostarlimab, Nivolumab, and Pembrolizumab? A Comprehensive Review

  2025cites this paper
• Decreased aggressive care at the end of life among advanced cancer patients in the Republic of Korea: a nationwide study from 2012 to 2018

  2024cites this paper
• A perspective on emerging therapies in metastatic colorectal cancer: Focusing on molecular medicine and drug resistance

  2024cites this paper
• Microbubble Enhanced Delivery of Vitamin C for Treatment of Colorectal Cancer

  2024cites this paper
• CHANGES IN CYTOKINE PROFILE AS A CRITERION FOR SEVERITY PREDICTION OF SKIN TOXICITY IN CANCER PATIENTS RECEIVING EGFRi.

  2024cites this paper
• Colorectal Cancer Management and Prevention Using Plant Polyphenols in the Rodent Models

  2024cites this paper
• Novel drug delivery systems in colorectal cancer: Advances and future prospects.

  2024cites this paper
• Transforming growth factor-β (TGF-β) signaling pathway-related genes in predicting the prognosis of colon cancer and guiding immunotherapy

  2023cites this paper
• Sevoflurane suppresses colorectal cancer malignancy by modulating β-catenin ubiquitination degradation via circSKA3.

  2023cites this paper
• Construction and validation of a novel angiogenesis pattern to predict prognosis and immunotherapy efficacy in colorectal cancer

  2023cites this paper
• Studies on 1,4-Quinone Derivatives Exhibiting Anti-Leukemic Activity along with Anti-Colorectal and Anti-Breast Cancer Effects

  2022cites this paper
• A novel enterocyte-related 4-gene signature for predicting prognosis in colon adenocarcinoma

  2022cites this paper
• Isolation and Identification of Long Non-Coding RNAs in Exosomes Derived from the Serum of Colorectal Carcinoma Patients

  2021cites this paper
• Magnetic Amine-Functionalized UiO-66 for Oxaliplatin Delivery to Colon Cancer Cells: In Vitro Studies

  2021cites this paper
• Sevoflurane inhibits malignant progression of colorectal cancer via hsa_circ_0000231-mediated miR-622

  2021cites this paper
• Momordin Ic induces G0/1 phase arrest and apoptosis in colon cancer cells by suppressing SENP1/c-MYC signaling pathway.

  2021cites this paper
• Synthesis, Characterization and Biological Studies on 3d-Metal Complexes of 5-[(1, 5-Dimethyl-3-oxo-2-Phenyl-2, 3-Dihydro-1H-Pyrazol-4-yl) Diazenyl]-1-Ethyl-6-Hydroxy-4-Methyl-2-oxo-1, 2-Dihydropyridine-3-Carbonitrile

  2021cites this paper
• High expression of FABP4 in colorectal cancer and its clinical significance

  2021cites this paper
• Long Non-Coding RNA CCAT2 Activates RAB14 and Acts as an Oncogene in Colorectal Cancer

  2021cites this paper
• MicroRNA‑3651 promotes colorectal cancer cell proliferation through directly repressing T‑box transcription factor 1.

  2020cites this paper
• Design and synthesis of new energy restriction mimetic agents: Potent anti-tumor activities of hybrid motifs of aminothiazoles and coumarins

  2020cites this paper
• Circular RNA 100146 Promotes Colorectal Cancer Progression by the MicroRNA 149/HMGA2 Axis

  2020cites this paper
• In vitro Biological Tests as the First Tools To Validate Magnetic Nanotheranostics for Colorectal Cancer Models

  2020cites this paper
• Analysis of the role of the interleukins in colon cancer

  2020cites this paper
• Effects of miR-135a-5p and miR-141 on proliferation, invasion and apoptosis of colorectal cancer SW620 cells

  2020cites this paper
• miR-146a-5p and miR-193a-5p Synergistically Inhibited the Proliferation of Human Colorectal Cancer Cells (HT-29 cell line) through ERK Signaling Pathway

  2020cites this paper
• Synthesis, spectroscopic characterization and pharmacological studies on novel sulfamethaxazole based azo dyes

  2020cites this paper
• Sevoflurane suppresses cell viability and invasion and promotes cell apoptosis in colon cancer by modulating exosome-mediated circ-HMGCS1 via the miR-34a-5p/SGPP1 axis

  2020cites this paper
• Tumour heterogeneity: Does it matter?

  2020cites this paper
• Combined blockade of EGFR and glutamine metabolism in preclinical models of colorectal cancer

  2020cites this paper
• Synthesis, Spectral Characterization and Pharmacological Evaluation of Ni(II) Complexes of 6-Nitro-benzothiazole Incorporated Azo Dyes

  2020cites this paper
• The Liquid Biopsy in the Management of Colorectal Cancer: An Overview

  2020cites this paper
• Sevoflurane inhibits migration and invasion of colorectal cancer cells by regulating microRNA-34a/ADAM10 axis.

  2019cites this paper
• The prognostic role of tumor associated glycoprotein 72 (TAG-72) in stage II and III colorectal adenocarcinoma.

  2019cites this paper
• Recruiting potent membrane penetrability in tumor cell-targeted protein-only nanoparticles

  2019cites this paper
• Antitumor activity in colorectal cancer induced by hinokiflavone

  2019cites this paper
• Self-antigen MASH2 combined with the AS15 immunostimulant induces tumor protection in colorectal cancer mouse models

  2019cites this paper
• Early Neuropathy Related to Oxaliplatin Treatment in Advanced and Recurrent Colorectal Cancer

  2019cites this paper
• Bioinformatics Analysis of Key Genes and Pathways in Colorectal Cancer

  2019cites this paper
• Mechanisms of multicellular drug resistance and novel approaches for targeted therapy in cancer

  2019cites this paper
• A novel azo metal complexes of 5, 5, 7-trimethyl-4, 5, 6, 7-tetrahydro-1, 3-benzothiazol as potential pharmacological agents: Synthesis and spectroscopic characterization

  2019cites this paper
• Novel Lysine-Based Thioureas as Mechanism-Based Inhibitors of Sirtuin 2 (SIRT2) with Anticancer Activity in a Colorectal Cancer Murine Model.

  2019cites this paper
• Value of tumor size as a prognostic factor in metastatic colorectal cancer patients after chemotherapy: a population-based study.

  2019cites this paper
• Tetrandrine inhibits colon carcinoma HT-29 cells growth via the Bcl-2/Caspase 3/PARP pathway and G1/S phase

  2019cites this paper
• Design and Synthesis of TASIN Analogues Specifically Targeting Colorectal Cancer Cell Lines with Mutant Adenomatous Polyposis Coli (APC).

  2019cites this paper
• Dysregulated microRNAs in colorectal carcinogenesis: New insight to cell survival and apoptosis regulation

  2019cites this paper
• Prognostic Nomogram and Patterns of Use of FOLFIRI-Aflibercept in Advanced Colorectal Cancer: A Real-World Data Analysis.

  2019cites this paper
• Analysis of risk factors for colon cancer progression

  2019cites this paper
• An Isoxazole Derivative SHU00238 Suppresses Colorectal Cancer Growth through miRNAs Regulation

  2019cites this paper
• MiR-519b-3p Inhibits the Proliferation and Invasion in Colorectal Cancer via Modulating the uMtCK/Wnt Signaling Pathway

  2019influential citation
• Up-regulation of microRNA-497-5p inhibits colorectal cancer cell proliferation and invasion via targeting PTPN3

  2019cites this paper
• The identification of CRNDE, H19, UCA1 and HOTAIR as the key lncRNAs involved in oxaliplatin or irinotecan resistance in the chemotherapy of colorectal cancer based on integrative bioinformatics analysis

  2019cites this paper
• Identification of new binding proteins of focal adhesion kinase using immunoprecipitation and mass spectrometry

  2019cites this paper
• Tumor heterogeneity: does it matter?

  2019cites this paper
• Expression and Clinical Significance of POLR1D in Colorectal Cancer

  2019cites this paper
• Differential expression of microRNAs in colorectal cancer: Different patterns between isolated cancer gland and stromal cells

  2019cites this paper
• Colorectal Cancer Growth Retardation through Induction of Apoptosis, Using an Optimized Synergistic Cocktail of Axitinib, Erlotinib, and Dasatinib

  2019cites this paper
• A systematic comparison of label-free, SILAC and TMT techniques to study early adaption towards inhibition of EGFR signaling in the colorectal cancer cell line Difi.

  2019cites this paper
• Risk Factors of Chemotherapy-Induced Neutropenia associated with FOLFOX, FOLFIRI, and FOLFOXIRI Regimens used in Patients with Advanced and Metastatic Colorectal Cancer

  2019cites this paper
• Oncogenic role of microRNA-532-5p in human colorectal cancer via targeting of the 5'UTR of RUNX3.

  2018cites this paper
• Correlation analysis of IL-4, IL-10 and APN levels with postoperative infection of colorectal cancer

  2018cites this paper
• Effect of fibroblast co-culture on the proliferation, viability and drug response of colon cancer cells

  2018cites this paper
• Radiolabeling, Characteristics and NanoSPECT/CT Imaging of 188Re-cetuximab in NCI-H292 Human Lung Cancer Xenografts

  2018cites this paper
• Development of recombinant oncolytic Coxsackievirus B3 for treatment of colorectal carcinoma

  2018cites this paper
• Management and grading of EGFR inhibitor-induced cutaneous toxicity.

  2018cites this paper
• Systematic evaluation of therapeutic efficacy and safety of traditional Chinese medicine injection ( TCMI ) combined with oxaliplatin-containing chemotherapy in the treatment of colorectal cancer

  2018cites this paper
• Human mast cells promote colon cancer growth via bidirectional crosstalk: studies in 2D and 3D coculture models

  2018cites this paper
• Dual HER2 inhibition strategies in the management of treatment-refractory metastatic colorectal cancer: History and status

  2018cites this paper
• Biological Activities of Lactose-Derived Prebiotics and Symbiotic with Probiotics on Gastrointestinal System

  2018cites this paper
• GNA13 promotes tumor growth and angiogenesis by upregulating CXC chemokines via the NF‐κB signaling pathway in colorectal cancer cells

  2018cites this paper
• Resistant starch prevents tumorigenesis of dimethylhydrazine-induced colon tumors via regulation of an ER stress-mediated mitochondrial apoptosis pathway

  2018cites this paper
• Polymorphisms in the ICOS/CD28‐ICOSL pathway are related to capecitabine‐based chemotherapy response in advanced colon cancer patients

  2018cites this paper
• Gomisin G Suppresses the Growth of Colon Cancer Cells by Attenuation of AKT Phosphorylation and Arrest of Cell Cycle Progression

  2018cites this paper
• Anti-VEGFR2-interferon-α2 regulates the tumor microenvironment and exhibits potent antitumor efficacy against colorectal cancer

  2017cites this paper
• Mir-30d suppresses cell proliferation of colon cancer cells by inhibiting cell autophagy and promoting cell apoptosis

  2017cites this paper
• Diazenyl schiff bases: Synthesis, spectral analysis, antimicrobial studies and cytotoxic activity on human colorectal carcinoma cell line (HCT-116)

  2017cites this paper
• Prevention and treatment of familial adenomatous polyposis and colorectal cancer by bilberry-derived anthocyanidins.

  2017cites this paper
• Identification and characterization of a novel SCYL3-NTRK1 rearrangement in a colorectal cancer patient

  2017cites this paper
• A Systematic Analysis of Oncogenic Gene Fusions in Primary Colon Cancer.

  2017cites this paper
• Wee1 inhibition can suppress tumor proliferation and sensitize p53 mutant colonic cancer cells to the anticancer effect of irinotecan.

  2017cites this paper
• Bispecific Antibodies (bsAbs): Promising Immunotherapeutic Agents for Cancer Therapy.

  2017cites this paper
• MAPK inhibitors induce serine peptidase inhibitor Kazal type 1 (SPINK1) secretion in BRAF V600E‐mutant colorectal adenocarcinoma

  2017cites this paper
• The BET-Bromodomain Inhibitor JQ1 synergized ABT-263 against colorectal cancer cells through suppressing c-Myc-induced miR-1271-5p expression.

  2017cites this paper
• High expression of long noncoding RNA AB 073614 in colorectal cancer patients and its clinical significance

  2017cites this paper
• Identification and characterization of a novel SCYL3-NTRK1 rearrangement in a colorectal cancer patient.

  2017cites this paper
• Therapeutic Inhibition of miR-4260 Suppresses Colorectal Cancer via Targeting MCC and SMAD4

  2017cites this paper
• Protein-Based Therapeutic Killing for Cancer Therapies.

  2017cites this paper
• Clinical Implementation of Precision Medicine: Current Challenges and Future Perspectives

  2016cites this paper
• Pakistan Veterinary

  year unknowncites this paper